

Ref: FOI/GS/ID 6946

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

26 October 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Triple-Negative Breast Cancer.

You asked:

Question 1 – In the past three months, how many patients were treated for Triple-Negative Breast Cancer with the following:

- a) Anthracycline (e.g. doxorubicin) as a single agent*
- b) Atezolizumab + nab-paclitaxel or paclitaxel*
- c) Capecitabine as a single agent*
- d) Eribulin as a single agent*
- e) Eribulin + other chemotherapy*
- f) PARP inhibitor (e.g. Olaparib)*
- g) Platinum (e.g. carboplatin, cisplatin) as a single agent*
- h) Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent*
- i) Other single agent chemotherapy*
- j) Other chemotherapy combination*
- k) Other immunotherapy containing regimen*
- l) Other active systemic anti-cancer therapy*

Question 2 – How many of these Triple-Negative Breast Cancer patients treated in the last three months received treatment that was:

- a) Privately funded*
- b) Part of clinical trial*
- c) Part of an early access scheme*

Trust response:

- 1.
- a) 0
- b) 0
- c) 0

- d) 0
 - e) 0
 - f) 0
 - g) 0
 - h) 0
 - i) 0
 - j) 4
 - k) 0
 - l) 0
- 2.
- a) 0
 - b) 0
 - c) 0